| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 450 | 2021 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 422 | 2021 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 311 | 2021 |
| Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update N Denduluri, M Chavez-MacGregor, ML Telli, A Eisen, SL Graff, ... Journal of Clinical Oncology 36 (23), 2433-2443, 2018 | 168 | 2018 |
| Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update N Denduluri, MR Somerfield, M Chavez-MacGregor, AH Comander, ... Journal of Clinical Oncology 39 (6), 685-693, 2021 | 87 | 2021 |
| Evaluating unconscious bias: speaker introductions at an international oncology conference N Duma, U Durani, CB Woods, LA Kankeu Fonkoua, JM Cook, C Wee, ... Journal of Clinical Oncology 37 (36), 3538-3545, 2019 | 72 | 2019 |
| MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis A Ghosh, S Sarkar, S Banerjee, F Behbod, O Tawfik, D McGregor, S Graff, ... PloS one 13 (5), e0198143, 2018 | 33 | 2018 |
| Racial disparity in breast cancer: can it be mattered for prognosis and therapy V Gupta, I Haque, J Chakraborty, S Graff, S Banerjee, SK Banerjee Journal of Cell Communication and Signaling 12, 119-132, 2018 | 32 | 2018 |
| The rise of the expert patient in cancer: from backseat passenger to co-navigator A Anampa-Guzmán, J Freeman-Daily, M Fisch, E Lou, NA Pennell, ... JCO oncology practice 18 (8), 578-583, 2022 | 26 | 2022 |
| Impact of closed Facebook group participation on female hematology/oncology physicians SL Graff, J Close, S Cole, L Matt-Amaral, R Beg, MJ Markham Journal of oncology practice 14 (12), e758-e769, 2018 | 26 | 2018 |
| Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. EP Hamilton, T Petit, B Pistilli, A Goncalves, AA Ferreira, F Dalenc, ... Journal of Clinical Oncology 38 (15_suppl), 3093-3093, 2020 | 21 | 2020 |
| Pregnancy after breast cancer in young BRCA carriers: an international hospital-based cohort study M Lambertini, E Blondeaux, E Agostinetto, AS Hamy, HJ Kim, A Di Meglio, ... JAMA 331 (1), 49-59, 2024 | 16 | 2024 |
| Incidence, nature, and consequences of oncologists' experiences with sexual harassment IM Subbiah, MJ Markham, SL Graff, LB Matt-Amaral, JL Close, KA Griffith, ... Journal of Clinical Oncology 40 (11), 1186, 2022 | 14 | 2022 |
| Newly approved and emerging agents in HER2-positive metastatic breast cancer SL Graff, F Yan, Y Abdou Clinical breast cancer, 2023 | 11 | 2023 |
| Social media and professional development for oncology professionals A Chidharla, A Utengen, DJ Attai, EK Drake, GJ Van Londen, IM Subbiah, ... JCO oncology practice 18 (8), 566-571, 2022 | 11 | 2022 |
| Critical aspects of a sustainable clinical research program in the community-based oncology practice JL Ersek, SL Graff, FP Arena, N Denduluri, ES Kim American Society of Clinical Oncology Educational Book 39, 176-184, 2019 | 9 | 2019 |
| Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial MP Goetz, NA Bagegni, G Batist, A Brufsky, MA Cristofanilli, S Damodaran, ... Annals of Oncology 34 (12), 1141-1151, 2023 | 8 | 2023 |
| Adjuvant abemaciclib plus endocrine therapy in the treatment of high-risk early breast cancer: ASCO guideline rapid recommendation update Q and A RA Freedman, SL Graff, MR Somerfield, ML Telli, AC Wolff, SH Giordano JCO Oncology Practice 18 (7), 516-519, 2022 | 8 | 2022 |
| postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a … K Kalinsky, RM Layman, PA Kaufman, SL Graff, G Bianchini, M Martin, ... Journal of Clinical Oncology 40 (16_suppl), TPS1117-TPS1117, 2022 | 8 | 2022 |
| Gender-specific conferences and symposia: a putative support structure for female physicians NC Woitowich, SL Graff, M Swaroop, S Jain Journal of Women's Health 29 (9), 1203-1208, 2020 | 8 | 2020 |
